Last update March 9, 2021
Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.
Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.
Thank you for helping to protect and promote breastfeeding.
Etoricoxib in other languages or writings:
Etoricoxib belongs to this group or family:
Main tradenames from several countries containing Etoricoxib in its composition:
|Oral Bioavail.||83 - 100||%|
|Tmax||1 - 2||hours|
|T½||22 - 25||hours|
Write us at firstname.lastname@example.org
e-lactancia is a resource recommended by Asociación Española de Bancos de Leche Humana of Spain
Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM
Non-steroidal anti-inflammatory drug (NSAID), that functions as a selective inhibitor of the cyclooxygenase-2 (COX-2) enzyme.
Prescribed for the treatment of osteoarthritis, rheumatoid arthritis, ankylosing spondylitis and acute gouty arthritis.
Daily oral administration in one dose.
We did not find published data regarding the excretion of this substance through breast milk at the time this last update was completed.
Pharmacokinetic data (large volume of distribution and high percentage of protein binding (CINFA 2020, MSD 2017) make it very unlikely for significant quantities to pass into breastmilk.
Until more published data regarding the interactions of this drug and breastfeeding are made available, the use of an alternative drug with a safer pharmacokinetic profile for lactation would be preferable, especially during the neonatal period or with premature infants.